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Abstract
A burgeoning body of research confirms and affirms the presence of aluminium in human brain tissue. Recently, the first data 
on aluminium content of brain tissue from donors with diagnoses of familial Alzheimer’s disease, autism spectrum disorder, 
multiple sclerosis and epilepsy have been published. Quantitative data are supported by aluminium-specific fluorescence 
microscopy identifying the locations of aluminium in human brain tissue. The challenge in the future will be to confirm or 
refute the role played by brain aluminium intoxication in human neurodegenerative disease.
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Human exposure to aluminium is burgeoning [1]. Living in 
the ‘aluminium age’ ensures that the myriad ways in which 
we are exposed to aluminium today will be even more 
numerous tomorrow. Aluminium in human brain tissue is 
the inevitable consequence of this burgeoning exposure [2]. 
However, what are the consequences of aluminium in human 
brain tissue? We know that aluminium does not benefit the 
human brain and in ‘excessive amounts’ it is neurotoxic. The 
latter label of ‘neurotoxicity’ is widely accepted for humans 
only because of the experience of relatively rare occurrences 
of iatrogenic disease [3] and especially dialysis dementia [4]. 
While aluminium in brain tissue is inevitable when is it also 
toxic? How can we define toxicity thresholds and when does 
neurotoxicity achieve a phenotype in affected individuals. 
How much aluminium in brain tissue is too much?
We reviewed aluminium in human brain tissue almost 
10 years ago [2] and in the period since, out with research 
in our group, there have not been any new quantitative data 
published on this subject. In 2012, we published the results 
of our 60 human brain study, an undertaking designed to 
provide robust and unequivocal data on the aluminium con-
tent of human brain tissue [5]. The research applied the most 
rigorous quality assurance methods possible including the 
measurement of 174 method blanks. We defined a method 
blank as an estimate of sample contamination from all 
experimental procedures beginning with taking tissue sam-
ples at the brain bank through to analyses of brain digests 
by transversely heated graphite furnace atomic absorption 
spectrometry (TH GFAAS). The only difference with sam-
ple treatments being that method blanks did not include 
brain (any) tissues. The median amount of aluminium pre-
sent as a contaminant was 22 ng/reaction vessel (used for 
microwave-assisted digestion) and since the method blank 
data were not normally distributed, a log transformation 
was used to determine a contaminant level of 54 ng/reac-
tion vessel (mean + 1.654SD). This value is, thereafter, 
subtracted from all tissue digests carried out using identi-
cal experimental procedures. The final data obtained for 60 
human brains were revealing in a number of ways. In the 
first instance, the median aluminium content for all 713 tis-
sue samples was 1.02 μg/g dry wt., an aluminium content in 
human brain tissue that might be thought of as inevitable (in 
donors aged 70–103 years) if not normal. However, scrutiny 
of data showed that in 41 of the 60 donors, the aluminium 
content of at least one tissue was above 3.00 μg/g dry wt., 
an aluminium content thereafter defined as pathologically 
significant [6]. While the brain bank that provided these tis-
sues refused (retrospectively) to reveal the disease state of 
the individual donors it is a matter of published record that 
for this particular brain bank approximately 50% of donors 
had a diagnosis of dementia at death [7]. As such, the 60 
human brain data set for aluminium constituted about 30 
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donors with a diagnosis of Alzheimer’s disease and 30 aged 
controls.
The nature of the aluminium data for the 60 human 
brains, range 0.01–33.00 μg/g dry wt., confirmed that which 
was already suspected, the focal as opposed to homogenous 
distribution of aluminium in human brain tissue [8]. It also 
questioned the value of brain tissue data based solely upon 
averages. Mean or median values would be informative 
where tissues were heavily overloaded with aluminium, but 
generally these statistics are more likely to hide important 
data on focal accumulations of aluminium. For example, not 
revealing areas of the brain where the aluminium content 
is sufficiently high to bring about, at the very least, focal 
neuropathology. We published the aluminium content of 
each of the three replicates of each tissue and eschewed the 
calculation of averages. We have continued the practice of 
publishing data for all replicates in all subsequent studies on 
aluminium in human brain tissue.
It is a rare privilege to work with human brain tissue, and 
weights of tissues available through brain banks are usually 
limited to less than 1 g. However, on some occasions, an 
opportunity arises to analyse larger weights of tissue and we 
had such an opportunity for a case of Alzheimer’s disease 
linked to occupational exposure to aluminium [9]. We were 
provided with approximately 20 g frozen weight of the fron-
tal lobe and this was divided into approximately 50 separate 
samples. Our 60-brain study had identified 0.3–0.5 g as the 
optimal range for fresh weight of brain tissue. Wet weights 
below 0.3 g could result in dry weights where the influ-
ence of contaminating aluminium might be disproportion-
ately high, whereas wet weights above 0.5 g were prone to 
incomplete digestion in the microwave. The concentration 
of aluminium (mean and SD) in the frontal lobe of brain 
tissue from this occupationally exposed individual was 2.98 
(2.73) μg/g dry wt. for 46 replicates. That 35% of the rep-
licates had a concentration of aluminium above 3.00 μg/g 
dry wt. confirmed a possible role for aluminium in this 
individual’s early-onset Alzheimer’s disease. Once again, 
as was the case for brain tissues in the 60-brain study, the 
range of concentrations was wide from the limit of detection, 
0.01–12.97 μg/g dry wt. and demonstrated the focal distribu-
tion of aluminium in human brain tissue.
Our subsequent studies have measured the aluminium 
content of brain tissue from donors who died with a diag-
nosis of familial Alzheimer’s disease (fAD) [10], autism 
spectrum disorder (ASD) [11], multiple sclerosis (MS) 
[12] and epilepsy [13]. In fAD the concentration of alu-
minium ranged from 0.01 to 35.65 μg/g dry wt. with 11 
out of 12 donor brains having at least one tissue where the 
aluminium content is considered as pathologically signifi-
cant (≥ 3.00 μg/g dry wt.). For ASD the concentration of 
aluminium ranged from 0.01 to 22.11 μg/g dry wt. with five 
out of five donor brains having at least one tissue where the 
aluminium content was considered as pathologically signifi-
cant (≥ 3.00 μg/g dry wt.). In MS donor tissue, aluminium 
concentrations ranged from 0.01 to > 50 μg/g dry wt. and 
all 14 donors had at least one tissue where the aluminium 
concentration was considered pathologically significant 
(≥ 3.00 μg/g dry wt.). Peer review of these published studies 
has consistently asked how brain aluminium data compare 
with control donor brains. In addressing this important criti-
cism, a pertinent question is what constitutes control tissue 
in brain aluminium research. For example, is brain tissue 
from a donor who has not died from a particular disease, 
e.g. MS, suitable control tissue for that condition? It should 
be recognised that aluminium is a toxin and its presence in 
brain tissue is only inimical. All biologically reactive alu-
minium will be disruptive and, at the very least, will require 
energy use in compensating its presence. At some point, 
compensating a toxic threshold of aluminium will manifest 
as neurodegeneration identifiable as such by an experienced 
pathologist. Brain banks are not replete with healthy brains. 
The majority of brains are from aged donors with under-
lying conditions. To understand the role of aluminium in 
neurodegenerative disease including AD, ASD and MS, age- 
and gender-matched healthy control brains are required. If 
available, such brain tissues would help in understanding if 
high concentrations of aluminium contribute towards neu-
rodegeneration, for example, high levels of aluminium with 
no coincident neurodegeneration would suggest otherwise. 
Similarly, data on healthy brain tissue would help to iden-
tify concentrations of aluminium that would not be expected 
to contribute towards neurodegeneration. We have worked 
with a major brain bank in the UK to identify donor brains 
in which there is little or no neurodegeneration. We have 
identified 21 brains, the majority from aged donors, and we 
are currently measuring their aluminium content to help to 
address the points raised above about what constitutes con-
trol brain tissue and what content of aluminium we might 
expect to find in brain tissue unaffected by overt neurode-
generative disease.
Quantitative measurements of brain aluminium are 
informative, but their interpretation with respect of neuro-
toxicity requires additional information. Previous research 
has suggested that the distribution of aluminium in brain 
tissue is focal, being, for example, associated with neuropa-
thology [2]. The recent development of aluminium-specific 
fluorescence microscopy [14] has not only been helpful 
in confirming the presence of aluminium in human brain 
tissue, but it has also identified the location of aluminium 
(Fig. 1). Imaging of aluminium has put quantitative data 
in context, for example, while both fAD and ASD showed 
some of the highest aluminium content, imaging identified 
clear differences in the location of aluminium. While in fAD 
deposits of aluminium were primarily extracellular [10], in 
ASD aluminium was mainly intracellular and associated 
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with non-neuronal cells such as microglia [11]. Imaging has 
also helped in identifying associations between aluminium 
and disease-specific neuropathology. For example, in fAD 
aluminium was co-localised with amyloid in senile plaques 
[10], whereas in cerebral amyloid angiopathy (CAA) depos-
its of aluminium were distinct from those of amyloid [15]. 
Similarly, while aluminium has been linked historically 
with neurofibrillary tangles in Alzheimer’s disease [16], 
tau and aluminium were not co-located in late-onset adult 
epilepsy [13]. In MS, imaging has identified aluminium in 
both extra- and intracellular locations as well as associated 
with neuropathology including plaque-like structures and 
corpora amylacea [12].
Aluminium-specific fluorescence microscopy has con-
firmed that aluminium is not distributed homogenously in 
brain tissue and this informs us that even when an aluminium 
concentration of 1.00 μg/g dry wt. (1 ppm) is determined for 
0.500 g fresh weight of tissue, there will be regions within 
this sample of tissue where the concentration of aluminium 
is significantly higher than 1 ppm. These total concentrations 
of aluminium will be sources of biologically reactive alu-
minium with the potential for toxicity and even cytotoxicity 
[6]. Local toxicity may result in cellular and neuronal dys-
function and evoke compensatory mechanisms in affected 
cell populations. Where the concentration of aluminium in 
0.500 g of fresh weight of tissue is in excess of 3.00 μg/g 
dry wt., there will be focal concentrations of aluminium in 
excess of 10 ppm and the consequent local toxicity will be 
more overt and compensatory mechanisms less effective. 
Neurotoxicity is inevitable under such conditions and alu-
minium will either initiate a disease process or accelerate 
any disease processes that may be ongoing [17].
The presence of aluminium in brain tissue is an intoxica-
tion. It will inevitably exert toxicity at a local level. Future 
research is required to ascertain the significance of discrete 
aluminium-related neurotoxicity and how the additive effects 
Fig. 1  Aluminium imaged in 
the human brain. Lumogal-
lion staining (1 mM in 50 mM 
PIPES, pH 7.4, 45 min.) of 
5 μm brain tissue sections 
from donors diagnosed with 
(a–c) autism spectrum disorder 
(ASD), d cerebral amyloid angi-
opathy (CAA), e epilepsy and 
f familial Alzheimer’s disease 
(fAD). Intracellular aluminium 
in astrocytes (a, white arrow), 
microglia b and in endothelial 
cells in the lumen of a blood 
vessel c in donors diagnosed 
with ASD in a white matter of 
the hippocampus b the frontal 
cortex and c white matter of 
the parietal lobe. Intracellular 
aluminium in a neuronal cell in 
a donor diagnosed with CAA in 
grey matter of the hippocampus 
(d). Extracellular aluminium 
in the temporal cortex of a 
donor diagnosed with epilepsy 
(e) and (f) co-localised with a 
senile plaque in white matter 
of the frontal lobe of a donor 
diagnosed with fAD. Magnified 
inserts are denoted with aster-
isks and images were acquired 
using an Olympus U-MNIB3 
fluorescence filter cube (excita-
tion: 470–495 nm, dichromatic 
mirror: 505 nm, longpass emis-
sion: 510 nm). Magnification 
×400, scale bars: 50 μm
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of such neuropathologies may eventually contribute towards 
recognised global neurodegenerative disease characteristic 
of conditions such as AD, MS, epilepsy and ASD.
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